GLP-1 receptor agonists and BPC-157 may share the peptide conversation, but their evidence is far from equal.
Before believing the hype, ask what was actually studied, in whom, and for how long. Which peptide claim should we examine next?
#
longevity# #
geroscience# #
peptides#